^
    Back
    Association details:
    Biomarker:BRAF V600K
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation

    Excerpt:
    ...- Signed written informed consent - Recheck the results of histological studies and paraffin blocks - Histologically confirmed cancer that is either Stage IIIc (unresectable) or ---Stage IV (metastatic), and determined to be BRAF V600E or V600K mutation-positive by the local laboratory. ...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases

    Excerpt:
    ...- Biopsy proven metastatic melanoma with the B-raf V600E or V600K mutations....
    Trial ID:
    NCT01781026
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

    Excerpt:
    ...- A confirmed EBRAFV600E or KBRAFV600K mutation....
    Trial ID:
    NCT01474551
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

    Excerpt:
    Twenty patients had BRAFV600E (67%), 9 had BRAFV600K (30%), and 1 had BRAFV600R melanoma (3%). Nearly all (28 of 30; 93%) patients experienced tumor regression with treatment. The median PFS was 22.0 weeks [95% confidence interval (CI), 13.0–31.0) and the median OS was 80.7 weeks (95% CI, 46.0–115.4; Table 1).
    DOI:
    10.1158/1078-0432.CCR-13-3122
    Trial ID:
    NCT01378975
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Research
    Title:

    RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

    Excerpt:
    In 17 melanoma cell lines, RG7204 was a potent inhibitor of proliferation in those expressing BRAFV600E but not BRAFWT (Fig. 1). RG7204 also potently inhibited proliferation of melanoma cell lines expressing other codon 600 BRAF mutations (V600D, V600K, and V600R).
    DOI:
    10.1158/0008-5472.CAN-10-0646